Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

Citations Over TimeTop 19% of 1988 papers

Abstract

3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described. Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8. The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compounds. Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.

Related Papers

• → Evidence for a common evolutionary origin of gastrin and cholecystokinin(1977)260 cited
• → Cholecystokinin and Gastrin Forms in the Nervous System(1985)30 cited
• → New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues(1986)49 cited
• → Gastrin and Cholecystokinin(1986)22 cited
• [Characteristics of brain gastrin/cholecystokinin-binding proteins].(1990)